BioMarin Pharmaceutical Inc.
Hedge Funds Holdings
Last updated:
BioMarin Pharmaceutical Inc.‘s stocks are currently a part of 531 hedge funds’ portfolios, which represents 95.2% of the total amount of its stocks outstanding. This makes up a total of 174.07M shares of BioMarin Pharmaceutical Inc.. Compared to the previous quarter, the number fell by -1.20% or -2.11M shares fewer. As for the holding position changes, 35.4% (188) of current hedge fund investors increased the number of shares held, 34.84% (185) of current holders sold a part of the shares held, and 13.18% (70) closed the holdings completely. 79 hedge funds are new holders of BioMarin Pharmaceutical Inc. stock in Q1 2022, it is 14.88% of total holders.
Hedge funds holding BioMarin Pharmaceutical (Q2 2017 – Q1 2022)
| Q2 2017 | 420 |
|---|---|
| Q3 2017 | 404 |
| Q4 2017 | 431 |
| Q1 2018 | 419 |
| Q2 2018 | 436 |
| Q3 2018 | 449 |
| Q4 2018 | 462 |
| Q1 2019 | 474 |
| Q2 2019 | 470 |
| Q3 2019 | 424 |
| Q4 2019 | 454 |
| Q1 2020 | 485 |
| Q2 2020 | 514 |
| Q3 2020 | 481 |
| Q4 2020 | 520 |
| Q1 2021 | 507 |
| Q2 2021 | 507 |
| Q3 2021 | 491 |
| Q4 2021 | 533 |
| Q1 2022 | 531 |
Hedge funds changes in BioMarin Pharmaceutical positions (Q2 2017 – Q1 2022)
| Q2 2017 | 48 | 157 | 149 | 36 | 30 |
|---|---|---|---|---|---|
| Q3 2017 | 38 | 158 | 147 | 47 | 14 |
| Q4 2017 | 82 | 148 | 139 | 48 | 14 |
| Q1 2018 | 48 | 146 | 153 | 56 | 16 |
| Q2 2018 | 62 | 163 | 138 | 44 | 29 |
| Q3 2018 | 47 | 171 | 151 | 31 | 49 |
| Q4 2018 | 64 | 147 | 186 | 50 | 15 |
| Q1 2019 | 53 | 200 | 158 | 38 | 25 |
| Q2 2019 | 60 | 168 | 169 | 55 | 18 |
| Q3 2019 | 33 | 166 | 158 | 77 | -10 |
| Q4 2019 | 80 | 176 | 131 | 46 | 21 |
| Q1 2020 | 81 | 179 | 158 | 46 | 21 |
| Q2 2020 | 91 | 200 | 160 | 61 | 2 |
| Q3 2020 | 63 | 181 | 179 | 95 | -37 |
| Q4 2020 | 97 | 190 | 168 | 56 | 9 |
| Q1 2021 | 76 | 177 | 182 | 85 | -13 |
| Q2 2021 | 53 | 180 | 176 | 52 | 46 |
| Q3 2021 | 49 | 186 | 160 | 58 | 38 |
| Q4 2021 | 99 | 180 | 172 | 47 | 35 |
| Q1 2022 | 79 | 188 | 185 | 70 | 9 |
Hedge funds changes in BioMarin Pharmaceutical stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 84,514,000 | 97,586,000 |
|---|---|---|
| Q3 2017 | 97,766,000 | 79,416,000 |
| Q4 2017 | 208,217,000 | 155,374,000 |
| Q1 2018 | 76,588,000 | 97,948,000 |
| Q2 2018 | 180,937,720 | 114,994,000 |
| Q3 2018 | 131,471,972 | 121,567,000 |
| Q4 2018 | 137,531,000 | 118,799,000 |
| Q1 2019 | 101,742,000 | 144,219,000 |
| Q2 2019 | 105,965,000 | 33,168,223,000 |
| Q3 2019 | 81,263,000 | 65,111,846,000 |
| Q4 2019 | 155,541,000 | 12,147,390,000 |
| Q1 2020 | 139,041,000 | 118,100,630,000 |
| Q2 2020 | 55,223,993,000 | 63,182,298,000 |
| Q3 2020 | 189,395,000 | 572,157,524,880 |
| Q4 2020 | 323,524,934 | 572,246,530,969 |
| Q1 2021 | 133,708,059 | 592,194,065,844 |
| Q2 2021 | 111,376,000 | 592,175,922,560 |
| Q3 2021 | 80,731,000 | 542,781,790,156 |
| Q4 2021 | 159,900,000 | 542,865,596,000 |
| Q1 2022 | 115,574,000 | 70,754,000 |